Supyra®

S Kant Healthcare

Product category
  • Seasonal malaria chemoprevention (sulfadoxine-pyrimethamine + amodiaquine)

Therapeutic indication
  • Seasonal malaria chemoprevention for children 3 to 59 months in eligible region

Dosing
  • Once daily for 3 days (amodiaquine) and one day (sulfadoxine-pyrimethamine), administered in monthly cycles for 4 months

Efficacy
  • 75% reduction in malaria episodes in pivotal trials

Key features
  • Recommended by WHO for the prevention of malaria in children in areas of high seasonal malaria transmission

Challenges
  • Drug distribution to healthy subjects mainly via door-to-door campaigns
Status
  • The Global Fund ERP approved for one year until Feb 2020
  • Registered in 5 countries; ongoing in 5 other countries
Next milestone
  • WHO prequalification

MMV Project Director
  • Dr André-Marie Tchouatieu